The Department of Defense officially terminated its contract with biotech company Sarepta for the development of an Ebola virus drug this week. While the company will continue to develop its Marburg virus drug under this contract, did the cancellation of this project have an effect on the company's share price? Didn't Sarepta have a stellar week after it released data related to its Duchenne's muscular dystrophy drug eteplirsen?
In the following video, health-care analysts Max Macaluso and David Williamson discuss this news and what investors should be watching at Sarepta going forward.
The article Why Investors Don't Care About This Sarepta News originally appeared on Fool.com.
Max Macaluso, David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.